Comparison Between Real-time Intra-operative Ultrasound-based Dosimetry and CT-based Dosimetry for Prostate Brachytherapy Using Cesium-131 www.tcrt.org The purpose of this study was to evaluate the correlation between real-time intra-operative ultrasound-based dosimetry (USD) and day 0 post-implant CT dosimetry (CTD) 131 Cs permanent prostate brachytherapy. Fifty-two consecutive patients who underwent prostate brachytherapy with 131 Cs were evaluated. Real time operating room planning was performed using VariSeed 7.1 software. Post-needle placement prostate volume was used for real-time planning. Targets for dosimetry were D 90 >110%, V 100 >90%, V 150 <50%, and V 200 <20%. The CT scan for post-operative dosimetry was obtained on day 0. The mean values for USD, CTD, and the linear correlation, respectively, were, for D 90 : 114.0%, 105.61%, and 0.15; for V 100 : 95.1%, 91.6%, and 0.22; for V 150 : 51.5%, 46.4%, and 0.40; and for V 200 : 15.8%, 17.9%, and 0.42. The differences between the mean values for USD and CTD for D 90 (p<0.01), V 100 (p<0.01), and V 150 (p<0.05) were statistically significant. For D90, 30.8% of patients had a >15% difference between USD and CTD and 51.9% of patients had a >10% difference between these values. In contrast, the USD and CTD for V 100 were within 5% in 55.8% of patients and within 10% in 86.5% of patients. This study demonstrates a correlation between the mean intra-operative USD and post-implant day 0 CTD values only for V 200 .
Introduction
Prostate brachytherapy has been accepted as an effective treatment for men diagnosed with clinically localized prostate cancer and has been demonstrated to have equal outcomes in terms of cancer control when compared to radical prostatectomy and external beam radiotherapy (1-5). Prostate cancer patients who choose prostate brachytherapy are attracted in part to the minimally invasive nature of the procedure, the quick return to full activity, and the low risk of urinary incontinence. Practitioners of prostate brachytherapy continue to strive to improve the outcomes of the procedure, both in terms of cancer control and quality of life. Post-implant dosimetry has assumed a major role in this effort, as post-implant dosimetry has been shown to correlate with biochemical recurrence free rates after the procedure (6, 7) . Volume 7, Number 6, December 2008 Post-implant dosimetry is recommended as the standard assessment of the quality of prostate brachytherapy as stated in the American Brachytherapy Society recommendations (8) . The adequacy of the implant is evaluated using parameters including the volume of the prostate that receives 100% of the prescription dose (V 100 ) and the dose delivered to 90% of the prostate volume (D 90 ) (9). Dosimetry outcomes after prostate brachtherapy should now be considered similar to surgical quality after radical prostatectomy (10). Dosimetry can be calculated both in real time in the operating room, usually based on ultrasound images; and post-operatively, usually based on CT imaging.
Several studies have suggested that real-time intra-operative USD correlates with post-operative CTD (9, 11). In order for real-time intra-operative USD to be an acceptable treatment, the dosimetry must be consistently reproducible among practitioners and must correlate to post-operative values within a specific time frame. In our case, post-operative dosimetry was obtained on day 0 for each patient and on days 14 and 30 for the first 30 patients. Because of the effect of volume on dosimetry, it is imperative to perform volume measurements as objectively as possible, and preand post-operative volumes must largely correlate in order to determine whether the dosimetry is accurate. If reliable dosimetry data can be calculated in the operating room, perhaps routine post-implant dosimetry evaluations can be eliminated. The studies that have reported that real-time intra-operative USD correlates with the post-implant CTD have evaluated 125 I and 103 Pd implants (10, (12) (13) (14) (15) .
Cesium-131 was recently introduced as a radionuclide for prostate brachytherapy by IsoRay Medical Inc. (Richland, Washington, USA) (16, 17) . The half-life of 131 Cs is approximately 9.7 days, which is less than the half-lives of 103 Pd (~17 days) and 125 I (~60 days) (18, 19) . Our prostate brachytherapy program has converted to the use of 131 Cs in hopes that the shorter half-life of 131 Cs may decrease the duration of urinary and bowel side effects after the procedure (20). The present study is the first to our knowledge that evaluates the correlation between real-time USD and day 0 post-implant CTD in men undergoing prostate brachytherapy with 131 Cs implants.
Methods and Materials
The first 52 patients who underwent prostate brachytherapy with 131 Cs implantation at our institution and had real-time USD calculated were included in the present retrospective study. The patients' demographic information appears in Table I . Thirty-four men (65.4%) underwent prostate brachytherapy as monotherapy, 11 men (21.2%) underwent combined radiotherapy (external beam radiotherapy combined with prostate brachytherapy), two men (3.8%) under-went prostate brachytherapy combined with androgen deprivation therapy, and five men (9.6%) underwent tri-modal therapy (androgen deprivation therapy plus external beam radiotherapy and prostate brachytherapy).
Volume measurements (via either ultrasound or CT) of the prostate were obtained prior to the implant in order to estimate the activity required for the implant. The procedure was performed on an outpatient basis under general anesthesia. At the time of the implant, the prostate volume and geometry were captured on ultrasound using a step section technique at 5 mm intervals from the base of the prostate to the apex. The urethra was visualized in both the transverse and sagittal views by placing aerated surgilube into the urethra.
Needles were then placed under real-time ultrasound imaging, and each needle was imaged in the transverse and sagittal views. Peripheral needles were placed first, approximately 8-10 mm apart and just under the capsule of the prostate in the largest transverse image. Two to eight (depending on prostate volume and shape) central needles were then placed to ensure adequate dosing of the central portion of the gland. After all needles were placed, post-needle prostate volume and geometry were captured by again contouring the prostate in transverse sections in 5 mm intervals from base to apex. Each needle location was registered and optimal seed placement was determined using treatment planning software (VariSeed 7.1, Varian Medical Systems, Palo Alto, CA, USA). Targets for dosimetry were: D 90 >110%, V 100 >90%, V 150 <50%, and V 200 <20%.
The radionuclide was implanted using an afterloading technique with a Mick applicator (Mick Nuclear, Bronx, NY, USA). Each needle was visualized in the sagittal plane when placing seeds through that needle, and the seeds were placed according to the treatment plan. After deposition of each seed, the actual seed position was registered onto the software. The computer then provided a real-time dynamic dosimetric evaluation of the implant as seed placement progressed. If an individual source was not well visualized, it was registered 2 mm forward of the needle tip. After all seeds were placed and their positions entered, D 90 , V 100 , V 150 , and V 200 were recorded and referred to as the USD. After the procedure, patients underwent a CT scan within 24 hours which served as the day 0 CT scan. Three millimeter slice resolution was used and the prostate was outlined on every CT slice. The D 90 , V 100 , V 150 , and V 200 were calculated from this CT and referred to as the CTD. The USD was compared to the CTD with Pearson's correlation coefficient and the difference between the two was evaluated by Student's t-test. A p-value ≤ 0.05 was considered statistically significant. The dosimetric parameters for each individual patient were also compared to assess the variation between USD and CTD for each patient.
Results
The mean USD parameters for D 90 , V 100 , V 150 , and V 200 are listed in Table IIa. The mean values were all within their target doses except for the V 150 , which was slightly above the goal of <50%. Mean values for day 0 CTD for D 90 , V 100 , V 150 , and V 200 are listed in Table IIb . The differences in the mean values between USD and CTD for D 90 and V 100 were statistically significant at p<0.01, while the difference in the mean values between USD and CTD for V 150 was statistically significant at p<0.05; the difference between the mean values for V 200 was not statistically significant (p= 0.13).
The mean relative difference ((USD-CTD)/CTD) was 8.8% for D 90 , 4.0% for V 100 , 17.1% for V 150 , and 4.9% for V 200 . However, the range of mean relative difference for D 90 was -20.6 to 42.0%, for V 100 was -16.0 to 27.0%, for V 150 was -47.8 to 134.2%, and for V 200 was -51.7 to 133.1%. The linear correlation between USD and CTD for D 90 was 0.15, for V 100 was 0.22, for V 150 was 0.40, and for V 200 was 0.42. The linear correlation was significant (p<0.005) for V 150 and V 200 .
The wide range in the mean relative difference is consistent with the large degree of variation that was found between the mean USD and CTD parameters for individual patients. As demonstrated in Figure 1 , 30.8% of patients had a greater than 15% difference between the D 90 for USD and CTD, while 51.9% of patients had a greater than 10% difference.
For V 150 , 55.8% had a greater than 15% difference between the USD and CTD values, while 69.2% of patients had a greater than 10% difference. For V 200 , 56.3% of patients had a greater than 15% difference between the USD and CTD values, while 82.4% of patients had a greater than 10% difference. The individual variation was not as marked for V 100 as 86.5% of patients had differences between mean values for USD and CTD within 10%. A comparison of the individual prostate volumes measured with intra-operative ultrasound and post-operative CT are demonstrated in Figure 2 .
Discussion
The present study suggest that real-time intra-operative USD is not an accurate surrogate for post-operative CTD, and that post-operative CTD is still necessary. Prostate brachytherapy is now clearly established as an effective option for the treatment of clinically localized prostate cancer (22) . Until recently, all permanent low dose rate prostate brachytherapy was performed with either 125 I or 103 Pd. Excellent biochemical outcomes at greater than 5 years after the procedure have been demonstrated and several reports have demonstrated prostate-specific antigen (PSA) relapse-free survival outcomes of 85-90% for low risk patients treated with brachytherapy. These results are comparable to reported outcomes after radical prostatectomy and external beam radiotherapy for patients with similar prognostic features (22-30). Patients Technology in Cancer Research & Treatment, Volume 7, Number 6, December 2008 are attracted to prostate brachytherapy in part due to its minimally invasive nature and the quick time to full recovery. However, many patients experience bothersome urinary and bowel symptoms and erectile dysfunction. With the use of 125 I and 103 Pd radionuclides, most patients do not return to their baseline voiding and bowel patterns or regain baseline erectile function until at least one year after the procedure (31-35). The half-life of 131 Cs is approximately 9.7 days, which is less than the half-lives of 103 Pd (17 days) and 125 I (60 days) (18, 19) . By using the 131 Cs radionuclide for prostate brachytherapy, it is hoped that its shorter half-life will result in a shorter duration of the bothersome urinary and bowel symptoms which commonly occur after prostate brachytherapy.
The present study is to our knowledge the first to investigate the relationship between real-time USD and post-operative CTD when 131 Cs is used for prostate brachytherapy. The mean values for D 90 , V 100 , and V 150 were different, while the mean value for V 200 was similar when USD and CTD were compared. Additionally, there was a wide range of variation for D 90 , V 150 , and V 200 when individual patients were compared. The values for V 100 , however, did not have a wide range of individual variation in the present study (Figure 3) . The mean relative difference ((USD-CTD)/CTD) and the range of variation increased from D 90 to V 150 to V 200 . Differences between intra-operative USD and post-operative CTD may be attributed to discrepancies in prostate volume measurements and to seed misplacement or migration; the seed space distribution tends to be less uniform in CTD and this can cause "hot spots" (14). We postulate that large differences in the mean V 150 and V 200 values between USD and CTD may be due to the effect of small geographic discrepancies on the measurement of small high-dose regions. The values for V 100 in the current study are largely between 90% and 100%. This narrow range for V 100 likely explains why there is less individual variation for this parameter in the present study. The Pearson correlation coefficient between USD and CTD increased from 0.15 for D 90 to 0.22 for V 100 to 0.40 for V 150 and 0.42 for V 200 . The improved correlation between V 150 and V 200 when compared to D 90 and V 100 is likely because variation in contouring between CT and US images has less influence when V 150 and V 200 are calculated. tween D 90 and V 100 obtained using real-time USD and CTD for 164 patients treated with both 125 I and 103 Pd radionuclides (10). Their results suggest that real-time USD could indeed serve as the final dosimetry record for the patient. Potters et al. also reported that patients treated with intra-operative dosimetry received less radioactivity per gram of the prostate with a corresponding small increase in the D 90 . These results raise the possibility that intra-operative dosimetry may allow for maximizing dose delivered to the prostate with greater precision and therefore decreasing the risk of morbidity. Potters et al. did not report individual variations. Chauveinc et al. also studied the relationship between realtime USD and post-operative CTD, and reported their results in 450 patients undergoing prostate brachytherapy with 125 I (12). They did report what they described as a "reasonable agreement" between these two values. However, they noted that when post-operative CTD and real-time USD were compared between individual patients, 11% of patients had a difference in their D 90 of >20% and 38% of patients had a difference in their D 90 of >10%.
Ohashi et al. did not find a correlation between real-time USD and post-implant CTD in 412 patients who underwent prostate brachytherapy with 125 I (13). Their results demonstrated a potential uncertainty of as much as 42.0% when attempting to convert intra-operative dosimetry to post-implant dosimetry. Nag et al. also found that USD does not accurately reflect the post-operative CTD for 125 I (14) . Their study demonstrated correlations between USD and CTD; however, large variations were found between individual patients in the dosimetric parameters studied. They reported a mean relative difference (USD-CTD/CTD) of 38% for D 100 , 16% for D 90 , 10% for V 100 , and 21% for V 150 .
Prostate brachytherapy dosimetry calculations are inherently inaccurate as they are dependent on where the outlines of the prostate and surrounding structures are drawn. Significant inter-observer and intra-observer error exists in dosimetry calculations (10, 36) . Tremendous subjectivity is associated with contouring a post-implant CT scan of the prostate. Seed artifact, edema, and experience all contribute to make the final dose plan subjective (10). Intra-operative USD is potentially even more inaccurate as the ultrasound image becomes significantly degraded as the procedure progresses due to the edema of the prostate, intra-prostatic hemorrhage, and air introduced into the prostate by needle placement. Potential inaccuracy in capturing seed location at the time of placement can also affect calculation of real-time dosimetry.
Another factor that may lead to differences between USD and CTD is that intra-operative dosimetry is obtained with the patient in the dorsal lithotomy position, while the CT is obtained with the patient in the supine position. This change in position likely also leads to a discrepancy between USD and CTD. Additionally, USD is obtained with an ultrasound probe in the rectum, which to at least some degree deforms the shape of the prostate.
CTD has been considered the reference standard for dosimetry after prostate brachytherapy. Real-time planning and dosimetry has several potential benefits. Most importantly, realtime dosimetry is a valuable tool as it allows for modification of the implant intra-operatively to help improve dosimetry results. The results of the present study, however, support those of other studies which have found that real-time USD does not serve as an adequate substitute for post-operative CTD.
Conclusion
This study does not demonstrate a correlation between the means for intra-operative USD and post-implant CTD in men undergoing prostate brachytherapy with 131 Cs. There is also a marked variation in D 90 , V 150 , and V 200 USD and CTD values for individual patients. The results of the present study suggest that real-time intra-operative USD is not an accurate surrogate for post-operative CTD, and that postoperative CTD is still necessary.
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